ArticleJournal of oral and maxillofacial pathology : JOMFP
Evaluation of p16 expression in oral and oropharyngeal squamous cell carcinoma.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 5 citations in OpenAlex.
- The superior prognostic role of pRB1 over p16 immunohistochemistry as a biomarker in meningiomas.Acta neuropathologica communications · 2026Article
- Diagnostic accuracy of combinatorial mRNA biomarkers for non-invasive detection and therapy monitoring of oral and oropharyngeal SCC.British journal of cancer · 2026Article
- Oncogenic viruses and their role in oral cavity and oropharyngeal squamous cell carcinoma: a systematic review.Frontiers in oncology · 2026Review
- Salivary biomarkers in oral cancer diagnosis: advancing conventional treatment strategies.Military Medical Research · 2026Review
- Current and Emerging Protein Biomarkers for the Diagnosis and Prognosis of Head and Neck Cancer.Genes · 2025Review
- Single nucleotide polymorphism and expression of P16 gene as a potential biomarker for oral and pre-oral cancer.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral and oropharyngeal cancers together are the 6 Aims: (1) To evaluate p16 expression in these cancers. (2) To correlate p16 expression with age, gender, sub-site, histological type and grade. (3) To utilize the Lewis/modified Lewis criteria. Methodology: The study included 70 cases of OSSC's and OPSCC's. Histological features were analyzed. p16 expression was determined and graded. Results were analyzed and evaluated using Chi-square test (value of Results: p16 positivity was seen in 46/70 (66%) cases (44 OSCC & 26 OPSCC). It was more frequent in younger patients and significantly higher in males. There was no correlation between degree of differentiation and p16 expression. In OSCC, 72.7% were p16 positive, mostly from tongue, buccal mucosa, and hard palate. p16 positivity was seen in 53.8% of OPSCCs, mostly from base of tongue and tonsil. Also, 30.4% of all cases could be included in Lewis criteria and 39.1% in modified Lewis criteria. Conclusion: p16 is an inexpensive, easily available marker, it may be incorporated routinely in all histologically diagnosed cases of OSCC and OPSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.